Multidimensional, integrative profiling identifies BCL2L1 methylation as a predictor of MCL1 dependency in pediatric...

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Pediatric high-grade gliomas (pHGGs) are aggressive childhood brain tumors with distinct biology from adult gliomas.
• Innovative therapeutic strategies are urgently needed to improve outcomes for pediatric cancer patients.

Purpose of the Study:

• To identify unique genetic dependencies in pediatric gliomas.
• To explore novel therapeutic targets and predictive biomarkers for pediatric high-grade gliomas.

Main Methods:

• Utilized CRISPR/Cas9 knockout screening across pediatric and adult high-grade glioma cell lines.
• Employed predictive modeling with multiomics data on childhood cancer cell lines.
• Analyzed BCL2L1 gene methylation patterns across various pediatric tumor types.

Main Results:

• Myeloid cell leukemia 1 (MCL1) was identified as a key antiapoptotic gene essential for pediatric gliomas, but not adult gliomas.
• MCL1 inhibition demonstrated potent anticancer activity in pediatric HGG cell lines, regardless of genotype.
• BCL2L1 methylation emerged as a predictive biomarker for MCL1 inhibitor response in vitro and in vivo.

Conclusions:

• MCL1 is a promising therapeutic target for pediatric high-grade gliomas and other BCL2L1-methylated pediatric cancers.
• BCL2L1 methylation serves as a broad predictor of MCL1 dependency, enabling patient stratification for targeted therapies.